Sofamor tops $100 million this quarter:
This article was originally published in Clinica
Memphis, Tennessee-based Sofamor Danek's three-month sales topped $100 million for the first time in the company's history. The orthopaedics company says domestic sales growth was led mainly by an increase in the number of instrumented spinal fusions. During the third quarter, the FDA issued a final rule reclassifying pedicle screw systems, after over three years of review. The company says the ruling is a "real victory" for the spinal implant industry and should hasten the end of Sofamor's pedicle screw-related litigation.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.